Imodium (Loperamide Hydrochloride)

Loperamide Hydrochloride binds to peripheral μ‑opioid receptors in the gut. This binding decreases the release of neurotransmitters that stimulate intestinal muscle contraction, slowing transit time and allowing more water to be reabsorbed, which results in firmer stools.

The appropriate dose of Imodium is determined by a healthcare professional based on the individual’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions or the product label for dosing guidance.

Safety data for Loperamide Hydrochloride in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Imodium.

To order Imodium, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details and any necessary import documentation.

Imodium (loperamide) is a peripherally acting opioid that specifically slows gut motility, whereas other antidiarrheals such as bismuth subsalicylate work by coating the intestinal lining and reducing inflammation. Loperamide generally provides faster symptom control but requires caution with certain drug interactions and in patients with specific infections.

Imodium should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Imodium is taken orally, usually as a tablet that is swallowed whole with a glass of water. The exact administration schedule, including the number of tablets and timing, should follow the prescribing clinician’s directions or the label instructions.

Serious risks include severe constipation or fecal impaction, toxic megacolon, allergic reactions, and cardiac arrhythmias such as QT prolongation, especially when taken with strong CYP3A4 inhibitors or in high doses. Patients should seek immediate medical attention if they experience symptoms like severe abdominal pain, vomiting, or irregular heartbeats.

Imodium should be avoided in individuals with known hypersensitivity to loperamide, those with bacterial enterocolitis (e.g., Clostridioides difficile infection), acute dysentery, or ulcerative colitis flare-ups. It is also contraindicated in children under two years of age and in patients taking strong CYP3A4 inhibitors without medical supervision.